NCT01265368View on ClinicalTrials.gov

A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

August 31, 2013

Study Completion Date

September 30, 2018

Conditions
Stage IV Renal Cell Cancer
Interventions
BIOLOGICAL

MGN1601

Genetically modified allogeneic (human) tumor cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM)

Trial Locations (3)

10117

Charité - Universtitäsmedizin Berlin, Klinik für Urologie, Berlin

30625

Medizinische Hochschule Hannover, Klinik für Hämatologie, Hämostaseologie, Onkologie und Stammzelltransplantation OE6860, Hanover

53127

Universitätsklinikum Bonn, Med. Klinik und Poliklinik, Hämatologie und Onkologie, Bonn

Sponsors

Lead Sponsor

Mologen AG
All Listed Sponsors
lead

Mologen AG

INDUSTRY

NCT01265368 - A Clinical Study to Assess Safety and Efficacy of a Tumor Vaccine in Patients With Advanced Renal Cell Carcinoma (ASET) | Biotech Hunter | Biotech Hunter